表紙
市場調查報告書
商品編碼
1025225

全球仿製藥市場預測(2020-2026)

Generic Drugs Market 2020-2026

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內,全球仿製藥市場預計將以顯著的複合年增長率增長。慢性病患病率的增加和仿製藥的成本效益是加速市場增長的關鍵因素。癌症、心血管疾病和糖尿病等慢性病的日益流行正在推動市場增長。根據國際糖尿病聯盟 (IDF) 的數據,2019 年將有大約 4.33 億成年人(20-79 歲)患有糖尿病。預計到2045年將達到7億。品牌糖尿病藥物仿製藥的增加有助於減輕患者的成本負擔,並推動市場增長。

本報告對全球仿製藥市場進行調查和分析,並提供有關市場概況、市場決定因素、細分市場、競爭狀況、區域分析、關鍵公司等的系統信息。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和當前市場趨勢
  • 規章制度

第三章競爭形勢

  • 公司股票分析
  • 關鍵戰略分析
  • 主要公司分析
    • 邁蘭 N.V.
    • 梯瓦製藥工業有限公司
    • 羽扇豆有限公司
    • 諾華國際股份公司
    • Sun Pharmaceutical Industries Ltd.

第 4 章市場決定因素

  • 增長因素
  • 抑製器
  • 市場機會

第 5 章市場細分

  • 按應用分列的全球仿製藥市場
    • 癌症
    • 化學氣相沉積
    • 肌肉骨骼疾病
    • 傳染病
    • 神經內科
    • 糖尿病
    • 其他
  • 按給藥途徑劃分的全球仿製藥市場
    • 口服
    • 本地
    • 可注射的
    • 吸入器

第六章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他亞太地區
  • 其他領域

第七章公司簡介

  • Abbott Laboratories
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Co.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals PLC
  • Lannett Co. Inc.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/S
  • Stada Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: OMR2023545

Global Generic Drugs Market Size, Share & Trends Analysis Report, By Application (Cancer, CVD, Musculoskeletal Diseases, Infectious Diseases, Neurology, Diabetes, and Others), By Route of Administration (Oral, Topical, Injectable, and Inhaler) and Forecast, 2020-2026

The global generic drugs market is estimated to grow at a significant CAGR during the forecast period. Some pivotal factors accelerating market growth include the rising prevalence of chronic diseases and the cost-effectiveness of generic drugs. A significant rise in the incidences of chronic diseases such as cancer, CVD, and diabetes is driving market growth. As per the International Diabetes Federation (IDF), in 2019, nearly 463 million adults (20-79 years) were suffering from diabetes. It is expected to reach 700 million by 2045. 

This leads to an increasing demand for generic medicines for diabetes which includes Glyburide, Tolazamide (Tolinase), Acetohexamide, Glimepiride (Amaryl), and Glipizide. Additionally, several generic equivalents of the drug metformin (earlier sold only as Glucophage XR or Glucophage) are now available. The combinations of metformin and glipizide (Metaglip) and metformin and glyburide (Glucovance) are available as generic drugs. The increasing availability of generic versions of branded diabetes drugs is supporting to reduce the cost burden on patients, which, in turn, is driving the market growth. 

Geographically, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (Row). In 2019, North America held the largest share in the market owing to the US FDA initiatives to increase the availability of generic medicines in the market. For instance, in October 2007, the US FDA introduced the Generic Initiative for Value and Efficiency (GIVE). As an initiative, GIVE will utilize existing resources to support the US FDA to advance and streamline the approval process of generic drugs. The initiative is intended to increase the availability of generic drugs. The increasing availability of generic-drug alternatives results in more cost-savings to consumers, as generic drugs cost nearly 30% to 80% lower compared to the brand name drugs.

Some key players in the market include Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Ltd., Novartis International AG, and Sun Pharmaceutical Industries Ltd. The market players are using some key strategies to increase their market share. For instance, in September 2020, Sun Pharmaceutical Industries Ltd. declared the launch of ILUMYA (tildrakizumab) Subcutaneous Injection 100 mg Syringe in Japan to treat adult patients suffering from plaque psoriasis who have an insufficient response to traditional therapies. ILUMYA is a humanized lgG1/k monoclonal antibody that is intended to selectively attach to the p19 subunit of IL23 and stops its interaction with the IL-23 receptor. This leads to an inhibition of the release of chemokines and proinflammatory cytokines. 

Research Methodology

The market study of the global generic drugs market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

Financial reports of companies involved in the market.

Whitepapers, research-papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Generic Drugs Market Research and Analysis by Application

Global Generic Drugs Market Research and Analysis by Route of Administration

The Report Covers

Comprehensive research methodology of the global generic drugs market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global generic drugs market.

Insights about market determinants which are stimulating the global generic drugs market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Mylan N.V.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Teva Pharmaceutical Industries Ltd.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Lupin Ltd.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Novartis International AG
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Sun Pharmaceutical Industries Ltd.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Generic Drugs Market by Application
    • 5.1.1. Cancer
    • 5.1.2. CVD
    • 5.1.3. Musculoskeletal Diseases
    • 5.1.4. Infectious Diseases
    • 5.1.5. Neurology
    • 5.1.6. Diabetes
    • 5.1.7. Others
  • 5.2. Global Generic Drugs Market by Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Topical
    • 5.2.3. Injectable
    • 5.2.4. Inhaler

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Amneal Pharmaceuticals LLC
  • 7.3. Aurobindo Pharma Ltd.
  • 7.4. Baxter International Inc.
  • 7.5. Cipla Ltd.
  • 7.6. Dr. Reddy's Laboratories Ltd.
  • 7.7. Eli Lilly and Co.
  • 7.8. Fresenius SE & Co. KGaA
  • 7.9. GlaxoSmithKline plc
  • 7.10. Glenmark Pharmaceuticals Ltd.
  • 7.11. Hikma Pharmaceuticals PLC
  • 7.12. Lannett Co. Inc.
  • 7.13. Lupin Ltd.
  • 7.14. Merck & Co., Inc.
  • 7.15. Mylan N.V.
  • 7.16. Novartis International AG
  • 7.17. Novo Nordisk A/S
  • 7.18. Stada Arzneimittel AG
  • 7.19. Sun Pharmaceutical Industries Ltd.
  • 7.20. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 2. GLOBAL GENERIC DRUGS IN CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL GENERIC DRUGS IN CVD MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL GENERIC DRUGS IN MUSCULOSKELETAL MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL GENERIC DRUGS IN INFECTIOUS DISEASESMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL GENERIC DRUGS IN NEUROLOGYMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL GENERIC DRUGS IN DIABETES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL GENERIC DRUGS IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 10. GLOBAL ORAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL TOPICAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 12. GLOBAL INJECTABLE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 13. GLOBAL INHALABLE GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 14. GLOBAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 16. NORTH AMERICAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 17. NORTH AMERICAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 18. EUROPEAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 19. EUROPEAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 20. EUROPEAN GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 21. ASIA-PACIFIC GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 22. ASIA-PACIFIC GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 23. ASIA-PACIFIC GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)
  • 24. REST OF THE WORLD GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 25. REST OF THE WORLD GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL GENERIC DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
  • 2. GLOBAL GENERIC DRUGS MARKET SHARE BY ROUTE OF ADMINISTRATION, 2019 VS 2026 (%)
  • 3. GLOBAL GENERIC DRUGS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD GENERIC DRUGS MARKET SIZE, 2019-2026 ($ MILLION)